In an ongoing Phase I trial evaluating this novel molecule as a single agent in pretreated advanced KRAS-G12C patients (NCT04449874), in the NSCLC cohort, divarasib displayed an ORR of 53.4%, including one complete response, and a median PFS of 13.1 months. Here, KRAS is linked to non-small cell lung carcinoma.